Clinical Trial Update: Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease [Phase 2]

View source ↗

Summary

This update outlines a Phase 2 clinical trial evaluating GT-02287 for efficacy, safety, tolerability, and biomarker effects in early Parkinson's disease; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• GT-02287

Snippet

Sponsor: Gain Therapeutics, Inc. | Conditions: Parkinson Disease | Phase 2 | Status: NOT_YET_RECRUITING